Product/Composition:- | Dolasetron tablets |
---|---|
Strength:- | 50 mg |
Form:- | Tablets |
Reference Brands:- | Anzemet(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Dolasetron is a 5-HT3 receptor antagonist that blocks serotonin in the gastrointestinal tract and brain, reducing nausea and vomiting. It effectively prevents chemo- and post-operative nausea, supporting symptom relief, enhanced comfort, and improved quality of life for patients undergoing cancer treatment or surgery.
Dolasetron tablets, marketed as Anzemet, are approved in the US by the FDA and in the EU via EMA for preventing nausea and vomiting associated with chemotherapy and surgery. Regulatory approval requires comprehensive dossiers including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews detailed clinical trial and quality data for timely approval, while the EMA ensures compliance with regional safety and quality standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper regional adherence supports swift approval, safe usage, and worldwide availability, helping patients manage chemotherapy-related nausea and enhance treatment compliance globally.